Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
The efficacy of telavancin, a bactericidal lipoglycopeptide, was compared to that of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) in a murine pneumonia model. Telavancin produced greater reductions in lung bacterial titer and mortality than did vancomycin and linezolid at human doses equivalent to those described by the area under the concentration-time curve. These results suggest the potential utility of telavancin for treatment of MRSA pneumonia.
Reyes
Noe
N
Theravance, Inc., South San Francisco, CA 94087, USA.
Skinner
Robert
R
Kaniga
Koné
K
Krause
Kevin M
KM
Shelton
Josephine
J
Obedencio
Glenmar P
GP
Gough
Alexander
A
Conner
Michael
M
Hegde
Sharath S
SS
D000617:Aminoglycosides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000188:drug therapy / Q000382:microbiology; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*
D000617:Aminoglycosides; D000890:Anti-Infective Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C487637:telavancin